Streamlining AAV Manufacturing with Novel-Plasmid Systems to Reduce Variability, Boost Productivity, & Accelerate Clinical Delivery
- Reducing complexity in upstream workflows: assessing the potential for novel plasmid systems to streamline production
- Presenting insights from Affinia’s adoption of a novel plasmid system – Improving VG titres and reproducibility across capsid serotypes
- Discussing how a novel plasmid system can reduce GMP plasmid demand, simplify raw material supply chains, and lower COGs – directly accelerating time-to-clinic for rare disease programs
- Evaluating potential for scaling up through transfection volume, process timing and control